clinical trial · NCT06765668
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
Impax Laboratories, LLC·phase4·recruiting·n = 220
Parkinson DiseaseCREXONT ER
brief summary
The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).
started
Feb 12, 2025
primary completion
Nov 1, 2025
completion
Aug 6, 2026
last updated
Aug 24, 2025
official title
Open-Label Phase 4 Study of CREXONT® (Carbidopa and Levodopa) Extended Release Capsules in Parkinson's Disease Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol